The Bridge approach

Specialist life sciences equity research, grounded in experience. Analyst-led, transparently funded and independent of capital-raising mandates.

Follow our research

New research and commentary from Bridge Life Sciences and Chris Kallos, on LinkedIn and Substack.

Experience shapes our research.

Our research draws on almost 30 years of life sciences equity research experience, including extensive international sell-side work. Led by Chris Kallos, Bridge Life Sciences specialises in ASX-listed small and mid-cap biotechnology, medical technology and healthcare companies.
‍
We bring scientific understanding, commercial analysis and valuation together to explain the investment case at every stage of development. Our experience helps us identify the evidence, assumptions and milestones that matter, while keeping the risks and uncertainties in view.

Rigorous analysis with a clear investment case.

Our rigorous research process combines scientific evidence, commercial analysis and financial modelling. Each report examines opportunities, funding needs and risks, with sources and valuation assumptions clearly presented. Accessible summaries precede detailed analysis, distilling the investment case and providing a clear entry point into the scientific, clinical and commercial complexities of each company.

Research without transaction mandates.

Bridge focuses solely on equity research, independent of any capital markets department. We do not arrange capital raisings, nor do we accept transaction mandates. Companies engage us purely for specialist analysis.

Specialist research. Wide investor reach.

01

Explain the science and investment case.

02

Reach investors beyond the shareholder base.

03

Support engagement through accessible analysis.

04

Keep research freely available online.

Company-funded. Analyst-led.

Companies commission our research; each report discloses who pays.
Fees fund the research service, not favourable conclusions. The analyst retains responsibility for the analysis, valuation and conclusions.

Making the value drivers visible.

Our research makes scientific progress, commercial potential and underlying valuation drivers clearer. Broad distribution helps listed companies reach potential investors beyond their existing shareholder base.

We support informed assessment by explaining the evidence, key milestones and risks. We do not make unfounded promises, such as improved liquidity, a broader shareholder base or a particular share-price outcome.

Read the latest research

General information only. See Legal and Disclaimer.